Efficacy Of Combination Therapy Vs. Single-Agent Treatments In Mafld Patients: A Prospective Cohort Study
Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis with concurrent metabolic dysfunction and insulin resistance. While dapagliflozin and metformin are established treatments for metabolic disorders, comprehensive comparisons of their individual versus combined effects in MAFLD patients remain limited. This study evaluated the differential effects of dapagliflozin-metformin combination therapy compared to monotherapy on glycemic control, lipid profile, and metabolic syndrome components in patients with ultrasound-diagnosed MAFLD.